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Objective: The common single nucleotide polymorphism (SNP) rs143383 in the 50 untranslated region
(50UTR) of growth and differentiation factor 5 (GDF5) is strongly associated with osteoarthritis (OA) and
inﬂuences GDF5 allelic expression in vitro and in the joint tissues of OA patients. This effect is modulated
in cis by another common SNP, also located within the 50UTR, whilst a common SNP in the 30UTR
inﬂuences allelic expression independent of rs143383. DNA variants can be common, rare or extremely
rare/unique. To therefore enhance our understanding of the allelic architecture of this very important OA
susceptibility locus we sequenced the gene for potentially functional and novel rare variants.
Method: Using the Sanger method we sequenced GDF5 in 992 OA patients and 944 controls, with DNA
changes identiﬁed by sequencing software. We encompassed the protein-coding region of the two GDF5
exons, both untranslated regions and approximately 100 bp of the proximal promoter of the gene.
Results: We detected 13 variants. Six were extremely rare with minor allele frequencies (MAFs) of
0.0006. One is in a predicted transcription factor binding site in the GDF5 promoter whilst two
substitute conserved amino acids. The remaining seven variants were common and are previously
known variants, with MAFs ranging from 0.025 to 0.39. There was a complete absence of variants with
frequencies in-between the extremely rare (n¼ 6) and the common (n¼ 7).
Conclusions: This is the ﬁrst report of the deep sequencing of an OA susceptibility locus. The absence of
rare variants informs us that within the regions of the gene that we have sequenced GDF5 does not
harbour any novel variants that are able to contribute, at a population level, to the OA association signal
mediated by rs143383 nor does it harbour, at a population level, any novel variants that can inﬂuence OA
susceptibility independent of rs143383.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Growth and differentiation factor 5 (GDF5), also known as
cartilage derived morphogenetic protein 1 (CDMP1), is an extra-
cellular signalling molecule that participates in the development,
maintenance and repair of bone, cartilage and other tissues of the
synovial joint1, with penetrant and rare deleterious mutations of
the GDF5 gene resulting in dominant skeletal defects2. Based on thiso: John Loughlin, Newcastle
keletal Research Group, 4th
School, Framlington Place,
in).
s Research Society International. Pfunctional knowledge the GDF5 gene was chosen by a Japanese
group for examination as a potential osteoarthritis (OA) suscepti-
bility locus3. A number of common GDF5 polymorphisms were
genotyped in cases and in controls and association to the common
single nucleotide polymorphism (SNP) rs143383, a T to C transition
located in the 50 untranslated region (50UTR) of the gene, was
observed. In subsequent studies association of this SNP with OA
was observed in Europeans, demonstrating that the association has
global relevance4e6. Functional studies have suggested that
rs143383 is itself the polymorphism inﬂuencing OA susceptibility
with the OA-associated T-allele mediating reduced GDF5 tran-
scription relative to the C-allele7,8. Furthermore, association of
rs143383 to other musculoskeletal phenotypes, including variation
in normal height, Achilles tendon pathology, fracture risk and
congenital dysplasia of the hip, has been reported. This highlightsublished by Elsevier Ltd. All rights reserved.
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phenotypes (pleiotropy) and of the potential role that develop-
mental factors can have on conditions that manifest in the mature
individual9e13.
The negative effect of the OA-associated T-allele of rs143383 on
GDF5 transcription is modulated by a second common poly-
morphism located in the 50UTR of the gene, rs143384; in a lucif-
erase assay using chondrogenic cells it was demonstrated that the
T-allele of rs143383 mediates a reduction in luciferase activity
when it is on the background of a T-allele of rs143384 but not when
it is on the background of the C-allele of this SNP8. Furthermore,
using RNA extracted from the joint tissues of OA patients, this study
demonstrated that a third SNP in GDF5, rs56366915 (referred to as
2250ct in ref7), which is located in the 30UTR, affects allelic
expression of GDF5 independent of rs143383.
Mouse models have further developed our understanding of the
role of GDF5 in skeletogenesis and joint maintenance. The bra-
chypodismmouse is homozygote for a frame-shift mutation of Gdf5
that causes a premature termination codon resulting in a null
allele14. These mice have a number of abnormalities including
a shortened appendicular skeleton, a decrease in the length of the
limb long bones, and soft tissue deformities that clearly demon-
strate the important role of GDF5 in normal development14e16. A
haplo-insufﬁcient mouse carrying one copy of the brachypodism
allele does not show such developmental abnormalities but does
show an increased propensity of developing an OA phenotype
when challenged17. This model, which from a molecular genetics
perspective mimics the effect of SNP rs143383 in human OA,
conﬁrms the importance of maintaining adequate levels of GDF5
for normal joint function and emphasizes again the detrimental
effects of quantitative alterations in its expression on joint tissue
maintenance.
Overall, the rs143383 polymorphism is a very signiﬁcant
contributor to OA susceptibility, albeit with modest effect sizes
(odds ratios< 1.2). This polymorphism is functionally complex,
with the allelic expression mediated by rs143383 being modulated
by another common SNP and with a third SNP inﬂuencing allelic
expression in an independent manner. Cataloguing the variation at
this gene is therefore critical to our full understanding of this
important locus and we set out to assess the allelic architecture of
GDF5 in OA populations from northern and southern Europe using
a deep-sequencing approach.
Patients and methods
Cases and controls
OA cases and controls were studied from the UK, Spain and
Greece. All were of Caucasian ethnicity. The UK cohort were north
Europeans of white British origin, the Spanish cohort were Euro-
peans of Spanish origin and the Greek cohort were Europeans of
central Greek origin. Therewere 992 cases that had each undergone
a total knee or a total hip joint replacement due to severe primary
OA and 944 controls that lacked clinical signs of the disease.
Comprehensive details about the cases and the controls have been
published7,18.
In the UK cohort there were 502 cases (383 females and 119
males; 220 knee cases and 282 hip) and 460 controls (184 females
and 276 males). The cases were ascertained using the criteria of
signs and symptoms of OA sufﬁciently severe to require joint
replacement surgery. The radiological stage of the disease was
a Kellgren and Lawrence grade of 2 or more in all cases with over
90% being grade 3 or 4. Inﬂammatory arthritis (rheumatoid,
polyarthritic or autoimmune disease) was excluded, as was post-
traumatic or post-septic arthritis. The cases had an age range of56e85 years. The controls had no signs or symptoms of arthritis or
joint disease (pain, swelling, tenderness or restriction of move-
ment) and had an age range of 55e89 years.
In the Spanish cohort there were 264 cases (214 females and 50
males, all knee cases) and 294 controls (207 females and 87 males).
Cases were selected as consecutive patients, aged 55e80 years of
age at the time of surgery, undergoing total knee replacement if
a rheumatologist considered them to suffer from severe primary
OA. Exclusion criteria were inﬂammatory, infectious, traumatic or
congenital joint pathology and lesions due to crystal deposition or
osteonecrosis. Controls were recruited among subjects older than
55 years of age undergoing preoperative work-up for elective
surgeries other than joint surgery and who did not show clinical
manifestations of OA.
In the Greek cohort there were 226 cases (200 females and 26
males, all knee cases) and 190 controls (137 females and 53 males).
The cases had a Kellgren and Lawrence grade of greater than 2 prior
to total knee replacement and were randomly selected. Individuals
with rheumatoid arthritis and other autoimmune diseases as well
as chondrodysplasias, infection-induced OA, and post-traumatic OA
were excluded. The cases had an age range of 40e92 years. The
controls had undergone treatment for injuries and fractures and
had an age range of 46e88 years. All controls had a Kellgren and
Lawrence grade of 0.
Ethical approvals for the use of the DNAs in OA genetic studies
were obtained from local ethical committees: Oxford for the UK
cohort, Santiago for the Spanish cohort and Larissa for the Greek
cohort.
DNA sequencing
Using 50 ng of DNA extracted from peripheral blood samples by
phenolechloroform or guanidine hydrochloride GDF5 was poly-
merase chain reaction (PCR) ampliﬁed with overlapping amplimers
and these were then subjected to dideoxy Sanger sequencing using
the BigDye v3.1 kit (Applied Biosystems) and 3130 Genetic Analyzer
capillary sequencers (Applied Biosystems). In the Spanish and
Greek cohorts the search for variants focused on the protein-coding
regions of the two exons of GDF5 and the intron/exon ﬂanking
sequences, whilst the UK search encompassed the protein-coding
regions, the intron/exon ﬂanking sequences, both UTRs and 100 bp
of the proximal promoter of GDF5 (Fig. 1A). The sequences of the
primers used are listed in Supplementary Table I. The Polyphred
and SeqScape software’s (Applied Biosystems) were used to align
sequences and to identify DNA changes. Novel variants were
conﬁrmed by designing a new PCR amplimer and repeating the
sequencing on a fresh aliquot of DNA.
Variant 1 was genotyped in the Spanish and Greek cohorts using
the SNaPshot minisequencing protocol (Applied Biosystems) and
the PCR forward primer 50TTCCGTTTCCAATTCCTGAG30, the PCR
reverse primer 50TGACTGAGGGCTTGAAGGAG30 and the SNaPshot
primer 50AACTAGGGGGAAAAAAAAACTGGAGCACACAAGCAGCAT
TACGCCATT30.
Results
Known variants
GDF5 is 4.9 kb in length and contains two exons coding for a 510
amino acid protein. We identiﬁed seven common variants that
were previously known to exist in the gene: rs143383, rs73094730,
rs143384, rs224331, rs224330, rs73611720 and rs56366915 (Fig. 1B,
Supplementary Table II). rs224331 and rs224330 were observed in
the UK, Spanish and Greek cohorts, since the region of GDF5 har-
bouring these two variants (exon 2) was encompassed in the
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Fig. 1. The sections of GDF5 sequenced and the location of the newly discovered variants. (A) The six amplicons used for the sequencing in the UK cohort and the four amplicons
used for the Spanish and Greek cohorts. (B) At the top the arrows point to the approximate location of each of the six novel variants. At the bottom the arrows point to the
approximate location of the seven known variants that are present in dbSNP and which we conﬁrmed.
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variants were observed only in the UK cohort, since the regions
harbouring these ﬁve variants (the 50 and 30 UTRs) were only
sequenced in this cohort (Fig. 1A).
None of the known variants identiﬁed by us demonstrated
association to OA (P< 0.05), with association analysis performed
unstratiﬁed and stratiﬁed by cohort, by sex and by joint (data not
shown). We were not particularly surprised by this result since it is
known that large sample sizes are required to generate robust
association to rs1433834e6 and by comparison our sample size is
small and underpowered. Furthermore, and as noted above,
rs224331 and rs224330 were the only SNPs with data available in
all three cohorts, thus reducing further any power for the ﬁve
variants with genotype data available only from the UK cohort.
There are several other GDF5 SNPs listed in dbSNP but these
either lack frequency data or have so far been shown to be poly-
morphic only in non-European samples. These are rs34534075,
rs61754581, rs28936397, rs76603468, rs61754580, rs28936683,
rs17853055, rs5841206, rs6120942 and rs79051206 (http://
www.ncbi.nlm.nih.gov/projects/SNP/). We did not detect these
variants despite their coverage in our sequence analysis and we
conclude therefore that they are not polymorphic in Europeans, at
least in the large sample that we have studied.
Novel variants
We identiﬁed six novel and extremely rare variants, all in the UK
cohort (Fig. 1, Table I). Each variant was detected in a single indi-
vidual, two in cases and four in controls. The six UK individuals
carrying a variant allele were each heterozygote for the variantTable I
The six novel variants detected in GDF5. Each variant was detected in single individuals
Variant Individual Wild-type allele Mutan
1 Control C A
2 Case G A
3 Case G A
4 Control C T
5 Control C T
6 Control C Gallele that they carried. Variant 1 was discovered in a female control
following the successful sequencing of 458 cases and 418 controls
and therefore has a MAF in the UK sample of 0.0006 (1 mutant
allele in 1752 chromosomes). Variants 2 (female casewith knee OA)
and 3 (male case with knee OA) were discovered following the
successful sequencing of 491 cases and 425 controls and therefore
have minor allele frequencies (MAFs) in the UK sample of 0.0005
(1 mutant allele of each variant in 1832 chromosomes). Variants
4 (male control) and 5 (female control) were discovered following
the successful sequencing of 474 cases and 389 controls and
therefore have MAFs in the UK sample of 0.0006 (1 mutant allele of
each variant in 1726 chromosomes). Variant 6 (female control) was
discovered following the successful sequencing of 495 cases and
436 controls and therefore has a MAF in the UK sample of 0.0005
(1 mutant allele in 1862 chromosomes). For variants 2e6 these
MAFs are upper-bound estimates, as the variants were not
observed in the Spanish or Greek samples. The region of GDF5
harbouring variant 1 was not included in the sequence analysis of
the Spanish and Greek cohorts. We therefore directly genotyped
this variant in these cohorts, using as a positive the UK female
carrying the variant. The variant was not detected in the Spanish or
Greek cohorts. Variant 1, like variants 2e6, was therefore observed
only in the UK cohort.
We then used bioinformatics tools to see if any of these novel
variants had the potential to alter the GDF5 protein or affect
transcription factor binding to the GDF5 gene. Variant 1 is located in
the promoter of GDF5, 41 bp upstream of the transcription initia-
tion site. Using the transcription factor binding proﬁle databases
Jaspar (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl), TFSearch
(http://www.cbrc.jp/research/db/TFSEARCH.html) and Alggenfrom the UK. The variants were not observed in the Spanish or in the Greek cohorts
t allele Location Predicted effect
Promoter Alteration of a SOX9 binding site
Exon 1 Synonymous, Gly67Gly
Exon 1 Non-synonymous, Gly81Arg
Exon 2 Synonymous, Gly285Gly
Exon 2 Synonymous, Asp287Asp
Exon 2 Non-synonymous, Thr469Arg
Fig. 2. The amino acid sequence alignments for variants 3 and 6. The amino acid sequences of variant 3, Gly81Arg (top, highlighted in blue), and of variant 6, Thr469Arg
(bottom, highlighted in red), were aligned with human wild-type GDF5 and with GDF5 of other species.
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dicted to abolish HSF and CAP binding sites, to create CdxA and Ubx
binding sites and to alter SOX9, SOX10 and NFATC2 binding sites.
The glycine to arginine substitution coded for by variant 3 is at
a residue conserved in mammals but not in vertebrates (Fig. 2). The
substitution was predicted to be benign by the PolyPhen database,
which predicts the functional effect of non-synonymous human
SNPs (http://genetics.bwh.harvard.edu/pph/). The threonine to
arginine substitution coded for by variant 6 is in the mature part of
the protein at a highly conserved residue, conserved in mammals
and other vertebrates. PolyPhen predicted this substitution to be
potentially damaging.
Absence of rare variants
Our sequencing of GDF5 did not detect any rare variants, that is
variants with a MAF in the region of 0.001e0.025 (i.e., 0.1e2.5%).
Instead, variants were either extremely rare (MAFs 0.0006, i.e.,
0.06%, n¼ 6) or common (MAFs> 0.025, i.e., 2.5%, n¼ 7), as
represented in Fig. 3.
Discussion
It is becoming increasingly apparent that loci harbouring major
susceptibility alleles for a particular trait are also likely to beNumber
of
variants
Minor allele frequency 
1
2
5
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Fig. 3. The number of variants at GDF5 displayed according to their MAFs in the UK
cohort.repositories for other alleles inﬂuencing that trait19. The growth and
differentiation factor 5 gene GDF5 contains a common functional
SNP, rs143383, the T-allele of which is signiﬁcantly associated with
the development of OA and of other musculoskeletal phenotypes.
From a previous study we had established that the effect of
rs143383 on allelic expression imbalance of GDF5 is inﬂuenced by
genotype at a second 50UTR SNP, rs143384, whilst the 30UTR SNP
rs56366915 correlates with allelic expression imbalance indepen-
dent of rs1433838. rs143384 and rs56366915 are both common
SNPs that are present in public databases. In this studywe therefore
set out to assess the allelic architecture of GDF5 to assess whether
this gene harboured other potentially functional variants that may
be of relevance to OA aetiology. As far aswe are aware this is the ﬁrst
example of a deep-sequencing analysis of an OA susceptibility locus.
We sequenced GDF5 in cohorts of OA cases and non-OA controls
from northern and southern Europe. This focus on cases and
controls, rather than on individuals drawn from the general pop-
ulation, increased our likelihood of detecting penetrant risk or
protective alleles. We demonstrated the accuracy of our sequencing
by detecting all of the knownvariants fromdbSNP that residewithin
the sections of the gene that we covered. We also demonstrated its
sensitivity by identifying six extremely rare variants, present in
single individuals from amongst the large cohort sequenced. Three
of these extremely rare variants are potentially functional; variant 1,
which is located in predicted transcription factor binding sites,
variant 3, which codes for the substitution of a conserved glycine
residue and variant 6, which codes for the substitution of a highly
conserved threonine residue. Since these variants are extremely rare
they cannot have an impact, at a population level, on OA suscepti-
bility, on allelic expression imbalance mediated by rs143383 or on
allelic expression imbalance independent of rs143383. If they are
functional then they may have an effect at the individual and family
level. Highly penetrant, deleterious mutations of GDF5 can result in
autosomal dominant brachydactyly, characterized by malformation
of the phalanges2. Ethical policies with regards to genetic studies do
not allow us to re-contact the UK individuals used in this study to
discuss the impact of genetics on their health, so it is not possible for
us to assess whether the individuals that harbour variant 1 (a
control), variant 3 (a case) or variant 6 (a control) have a skeletal
phenotype that was missed at their recruitment. Of the two non-
synonymous variants that we detected, Gly81Arg was predicted to
be benign by the PolyPhendatabasewhilst Thr469Argwas predicted
to be potentially damaging. Neither of these residues have been
reported to be sites for brachydactyly mutations (http://
www.hgmd.cf.ac.uk/ac/index.php).
In conclusion, our deep sequencing of the transcript sequence
and promoter of GDF5 has revealed that this gene harbours
A.W. Dodd et al. / Osteoarthritis and Cartilage 19 (2011) 430e434434extremely rare variants and that it harbours common variants but
that there is an absence of variants of intermediate frequency. In
Europeans there are therefore unlikely to be additional proximal
variants of this locus that, at a population level, inﬂuence allelic
expression imbalance of the gene and contribute to OA suscepti-
bility. The currently known variants should be the target for future
functional studies.
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